Embracing the unordinary
How we drive change
Leading in obesity
For over 20 years, we’ve pioneered research and innovation for this global health crisis.
Driving innovation
We’re addressing the unmet needs of patients through unordinary innovation.
Increasing access
We’re meeting people where they are so that they can get the medicines they need.
Latest news
September 17 2025
Novo Nordisk’s oral semaglutide 25 mg (Wegovy® in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Read more
August 31 2025
Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Read more
August 18 2025
Novo Nordisk lowers cost of Ozempic® to $499 per month for self-paying patients, in support of patient access to authentic, FDA-approved semaglutide medicines
Read more
Know the risks of counterfeit semaglutide
Latest on compounded and counterfeit products and other important information about semaglutide.
Career opportunities
Here are our current job openings. If we don’t currently have an opening in your area of interest, we encourage you to create a job agent and candidate profile.
We offer 62 job opportunities